🕵️ Estrella Immunopharma, Inc. ($ESLAW)
SEC insider & ownership activity, last 12 months · CIK 1844417 · every row links its SEC filing
Insider buy value was withheld pending verification over the last 12 months. 3 red-flag 8-Ks in the window, most recently Delisting notice (3.01), Sep 1, 2026.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
1 buyer, value withheld pending verification (3 lots) · 0 sellers, $0 (0 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| Xu Jiandong | 3 | value withheld pending verification | 0 | – | Oct 7, 2025 |
5%+ holders
No current 5%+ beneficial-ownership positions on file.
Planned insider sales (Form 144)
No sale notices filed in the last 12 months.
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Delisting notice (3.01) | Sep 1, 2026 | filing ↗ |
| Delisting notice (3.01) | Aug 17, 2026 | filing ↗ |
| Shareholder vote (5.07) | Jun 29, 2026 | filing ↗ |
| Delisting notice (3.01) | Jan 7, 2026 | filing ↗ |
| Material agreement (1.01) | Jan 5, 2026 | filing ↗ |
| Unregistered equity sale (3.02) | Jan 5, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jan 5, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jan 5, 2026 | filing ↗ |
| Other events (8.01) | Dec 4, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Dec 4, 2025 | filing ↗ |
| Other events (8.01) | Nov 3, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 3, 2025 | filing ↗ |
| Other events (8.01) | Sep 23, 2025 | filing ↗ |
| Officer/director changes (5.02) | Sep 22, 2025 | filing ↗ |